Skip to main content

View full-text article in PMC

. 2021 Dec 20;37(1):380–396. doi: 10.1080/14756366.2021.2015342

Table 7.

Toxicity properties of the synthesised compounds.

Comp.	FDA rodent carcinogenicity (mouse-female)	Carcinogenic potency TD₅₀ (mouse)^a	Rat maximum tolerated dose (feed)^b	Rat oral LD₅₀^b	Rat chronic LOAEL^b	Skin irritancy	Ocular irritancy
5	Non-carcinogen	15.349	0.042	0.700	0.032	Non-irritant	Mild
6	Non-carcinogen	20.304	0.054	0.876	0.031	Non-irritant	Mild
7	Multi-carcinogen	23.695	0.045	0.386	0.041	Non-irritant	Mild
8	Non-carcinogen	18.535	0.045	0.991	0.020	Non-irritant	Mild
9	Non-carcinogen	11.722	0.045	1.412	0.017	Non-irritant	Mild
10	Non-carcinogen	13.868	0.043	0.368	0.016	Non-irritant	Mild
11	Non-carcinogen	14.625	0.052	1.614	0.020	Non-irritant	Mild
12	Non-carcinogen	9.203	0.042	0.246	0.026	Non-irritant	Mild
13	Non-carcinogen	6.298	0.066	0.915	0.012	Non-irritant	Mild
14	Non-carcinogen	4.964	0.053	0.473	0.014	Non-irritant	Mild
15	Non-carcinogen	6.520	0.053	0.660	0.015	Non-irritant	Mild
16	Non-carcinogen	22.826	0.040	2.753	0.028	Non-irritant	Mild
17	Non-carcinogen	9.752	0.040	1.832	0.014	Non-irritant	Mild
18	Non-carcinogen	21.184	0.132	1.669	0.032	Non-irritant	Mild
Sorafenib	Non-carcinogen	17.535	0.077	0.890	0.004	Non-irritant	Mild

^aUnit: mg/kg body weight/day.

^bUnit: g/kg body weight.